NASDAQ · STOCK
Illumina, Inc.
$205.10
52W $88.00 – $205.93
55/100
$31.03B
37.9
1.48
Is ILMN Bullish or Bearish?
Mixed.
Innellis AI committee rates Illumina, Inc. (ILMN) Watch with a composite score of 55/100
, based on 6 analysts with 67% agreement.
Last updated July 31, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +5.12 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -14.88 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
Some positive signals exist — 5 consecutive earnings beats -- consistent execution — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull & Bear Case
Bull Case
- ROE of 34.0% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- P/E of 34.9 is moderate-to-rich — Value
- Price-to-book of 7.5x prices in significant intangible value — Value
- RSI at 72 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
- Weekly RSI at 86 -- overbought on the larger timeframe too — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of July 31, 2026
Overall Committee Score
55/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 58%
of 93 Healthcare peers
Value Analyst
neutral
48
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 34.0% shows genuine earnings power backing the valuation
− P/E of 34.9 is moderate-to-rich
Growth Analyst
bullish
68
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ 5 consecutive earnings beats -- consistent execution
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 72 is in overbought territory
Macro Analyst
neutral
58
/ 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Investment Thesis Evolution
Committee score moved marginally from 55.4 to 54.9.
- New bearish signals: 6 appeared.
- Bullish support removed: 2 signal(s) disappeared.
- New bullish signals: 4 appeared.
- Bearish pressure eased: 5 signal(s) disappeared.
- Analyst(s) changed stance: Growth Analyst, Macro Analyst.
Analyst-level changes:
- Growth Analyst: stance neutral->bullish; score 52->68 (+17); +2 bullish signal(s).
- Macro Analyst: stance bullish->neutral; score 65->58 (-8); +2 bullish signal(s).
- Portfolio Manager: +2 bearish signal(s).
- Technical Analyst: score 58->48 (-10); +3 bearish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-07-30 to 2026-07-31 (1 day apart).
Technical Analysis
RSI (14)
71.3
Overbought
MACD Histogram
0.283
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Hh Hl
Support
$191.91
Resistance
$225.38
Bollinger %B
1.09
Above Upper Band
Price vs Moving Averages
EMA 9
$196.76
Above
EMA 21
$190.64
Above
EMA 50
$176.95
Above
EMA 200
$144.70
Above
Fundamental Analysis
Valuation
36
Growth
55
Profitability
1
Financial Health
82
Cash Flow
37
Valuation
P/E Ratio
37.9×
P/B Ratio
10.91×
PEG Ratio
-1.19
Dividend Yield
0.00%
52W High
$205.93
52W Low
$88.00
Quality & Growth
ROE
31.2%
ROA
12.8%
Gross Margin
66.8%
Operating Margin
21.0%
Revenue Growth YoY
—
Debt / Equity
0.86
AI Fundamental Assessment
P/E ratio of 37.9 (rich relative to a 15-40x range); Price-to-book of 10.9x; PEG ratio of -1.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.3%; Return on assets of 0.1%; Net margin of 0.2%; Gross margin of 0.7%; Current ratio of 1.80 (healthy short-term liquidity); Debt-to-equity of 0.86; Free cash flow margin of 0.9% (thin cash generation); Free cash flow per share is positive (6.22); Most recent quarter missed estimates by 5.3%; EPS growth decelerating (+13.9% -> +0.0% QoQ); Average YoY EPS growth of 10.1%; Analyst estimates rising over recent quarters
Get the Full ILMN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →